2
We offer the most advanced, evidence-based GLP-1 and GIP receptor agonists available, with the protocol matched to each patients goals, tolerance, and medical profile
GLP-1 medications like Ozempic, Mounjaro and Wegovy are already part of the mainstream in the US
230,231 By modulating the activity of K-ATP channels, GLP-1 indirectly controls the calcium signaling in -cells, thereby influencing glucagon secretion
A few hours earlier or later makes no meaningful difference
The realistic timeline Based on the current state of the clinical program, regulatory precedent, and publicly available information from Eli Lilly, here is the most realistic projection: Mid to late 2026: Remaining TRIUMPH, TRANSCEND, and SYNERGY Phase 3 results are reported